ERNESTO GUEVARA: Open Payments
NPI 1093342818 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,219 in 66 payments from 11 companies in 2025. Trend: 2023 $1,551 · 2024 $4,946 · 2025 $1,219
Food & beverage: $1,108Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $253 |
| Otsuka America Pharmaceutical, Inc. | 12 | $253 |
| Alkermes, Inc. | 12 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $159 |
| ABBVIE INC. | 15 | $155 |
| Neurocrine BioSciences, Inc. | 5 | $119 |
| Indivior Inc. | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Lundbeck LLC | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
Products named: ARISTADA, CAPLYTA, VRAYLAR, INGREZZA, AUSTEDO XR, ABILIFY ASIMTUFII, REXULTI, ABILIFY MAINTENA.
Industry payments across FL — which companies pay providers there.
